Login to Your Account



Lilly's Verzenio gets breast cancer nod, faces Ibrance, Kisqali

By Jennifer Boggs
Managing Editor

Thursday, September 28, 2017

Eli Lilly and Co.'s abemaciclib won FDA approval Thursday, making it the third CDK 4/6 inhibitor indicated for treating adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription